Companies

REGN · Biotech

REGENERON PHARMACEUTICALS, INC.

SEC company filings

Reported cash

USD 3,659,100,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

AI Company Brief

Form 8-K filed — 8-K; 2026-10-30.

Only filing metadata is tracked; the filing text or exhibits would be needed to establish substantive financial or regulatory developments.

Based on data through Oct 30, 2026

Upcoming catalysts

Next verified event · FDA target date

Ordspono · February 2027

relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Announced Oct 30, 2026 · Announced window

Official announcement
Source wording

The FDA accepted for review the resubmission of the BLA for Ordspono™ (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which has a target action date in February 2027.

FDA target date

Libtayo · March 2027

Announced Oct 30, 2026 · Announced window

Official announcement
Source wording

In October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo across all approved indications. The positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment. The European Commission (EC) is expected to make a final decision in the coming months. There is also a supplemental Biologics License Application (sBLA) under review by the U.S. Food and Drug Administration (FDA), which has a target action date in March 2027.

Drug pipeline

0 programs · 0 verified studies

No verified studies linked yet.

806 unverified sponsor matches remain unlinked.

Verified timeline

4 records
SEC · 8-K

Form 8-K filed

0000872589-26-000032

Item 2.02 · Results of Operations and Financial Condition

Item 9.01 · Financial Statements and Exhibits

Official EDGAR filing
SEC · 8-K

Form 8-K filed

0001104659-26-113895

Item 1.01 · Entry into a Material Definitive Agreement

Item 2.02 · Results of Operations and Financial Condition

Item 8.01 · Other Events

Official EDGAR filing
SEC · 8-K

Form 8-K filed

0001104659-26-112340

Item 5.02 · Departure or Appointment of Directors or Officers; Compensatory Arrangements

Item 9.01 · Financial Statements and Exhibits

Official EDGAR filing